aiwiki.page
English
Health / Drugs / polypharmacy

Polypharmacy

Polypharmacy is the concurrent use of multiple medicines, often defined as five or more, with clinical significance determined by their appropriateness and combined effects.

21 keywords1 linked from8 not yet writtenWritten by AI
Patient SafetyPrevalenceDiabetes Mellitu…Atrial fibrillat…Health SystemPharmacokineticsPharmacodynamicsWarfarinPolypharma…

Polypharmacy is the concurrent use of multiple medicines by one person. It is commonly defined in research as the use of five or more medicines, although no universally accepted numerical threshold exists. Polypharmacy can be clinically appropriate when several treatments are needed, but it can also involve unnecessary medicines, harmful combinations, or regimens whose burdens outweigh their benefits. It is an important concern in patient safety, particularly among people with several long-term conditions and older adults.

Definitions and measurement

Polypharmacy has both quantitative and qualitative meanings. Numerical definitions count medicines without necessarily judging whether their use is justified. Five or more is a common threshold; ten or more is sometimes called hyperpolypharmacy or excessive polypharmacy. These labels describe medication counts rather than establish that treatment is inappropriate.

Appropriateness-based definitions consider whether each medicine has a valid indication, whether its expected benefits outweigh its risks, and whether the overall regimen fits the person’s clinical circumstances and treatment goals. Appropriate polypharmacy can therefore coexist with a high medicine count. Conversely, a regimen containing only a few medicines can still be unsafe or unnecessary.

Studies differ in what they count. Some include only regular prescription medicines, whereas others include nonprescription products, supplements, herbal preparations, and medicines taken as needed. Fixed-dose combination products may be counted as one product or as several active ingredients. Measures may capture use on a single date or overlapping prescriptions over a specified period. These differences substantially affect estimates of prevalence and limit comparisons between populations.

Clinical context and contributing factors

A major driver is multimorbidity, the coexistence of multiple long-term health conditions. A person with heart failure, diabetes mellitus, and atrial fibrillation, for example, may have several distinct indications for treatment. Applying separate disease-specific guidelines can produce a complex combined regimen even when each prescription is individually justified.

Other contributing factors include:

  • Treatment by several prescribers who may not share a complete medication record.
  • Prescriptions continued after the original indication has resolved.
  • Duplicate treatment with medicines having similar effects.
  • Addition of medicines to manage adverse effects of existing treatment.
  • Changes in treatment during hospital admission, discharge, or transfer between care settings.
  • Use of nonprescription or complementary products that are not recorded in clinical records.

Polypharmacy is especially studied in older populations, but it also occurs in younger adults and children with complex illnesses. Its frequency depends on disease burden, prescribing practices, access to care, and the organization of the health system.

Mechanisms of medication-related harm

A high medicine count increases the complexity of treatment and creates more opportunities for adverse effects and interactions. The clinical risk depends on the particular medicines, doses, duration of use, organ function, and individual susceptibility—not simply on the number of products.

Drug interactions

Drug interactions can alter the concentration or effects of a medicine. Interactions involving pharmacokinetics affect absorption, distribution, metabolism, or elimination. Interactions involving pharmacodynamics alter the combined physiological effects of medicines, such as additive sedation or increased bleeding risk.

For example, concurrent use of warfarin and a nonsteroidal anti-inflammatory drug can increase bleeding risk. Not every potential interaction results in harm, however; clinical significance depends on exposure and context.

Cumulative effects and changing physiology

Several medicines can contribute to the same unwanted effect even if no single pair is identified as a major interaction. Sedative effects may accumulate, and multiple medicines with anticholinergic activity can collectively affect cognition, bowel function, and other bodily processes.

Age-related physiological changes and conditions such as chronic kidney disease can reduce the elimination of some medicines. A previously tolerated regimen may therefore have different effects as health status changes.

Prescribing cascades

A prescribing cascade occurs when an adverse effect of a medicine is interpreted as a new medical condition and another medicine is added to treat it. This can increase treatment complexity and expose the person to further adverse effects. Treatment of an adverse effect is not automatically inappropriate; the defining concern is whether the relationship to the original medicine has been recognized and evaluated.

Treatment burden

Complex regimens can involve multiple dosing times, monitoring requirements, administration difficulties, and financial costs. Such burdens can affect medication adherence and everyday functioning. The medicines listed in a clinical record may not fully reflect what a person actually takes, particularly when records are fragmented or instructions have changed.

Associations with health outcomes

Observational studies have associated polypharmacy with adverse drug events, falls, hospital admission, functional impairment, and mortality. These associations require cautious interpretation.

People taking more medicines often have more severe illness, greater frailty, or more complex care needs. These factors can themselves cause poor outcomes, making it difficult to isolate the effects of medicine count. Statistical adjustment does not necessarily remove all such confounding.

Medication number is therefore useful as a marker of potential complexity, but it is not a sufficient measure of prescribing quality. Relevant outcomes include symptoms, disease control, treatment burden, adverse effects, and health-related quality of life, rather than reduction in medicine count alone.

Clinical assessment and medication optimization

Medication optimization evaluates the regimen as a whole rather than treating a numerical threshold as a target. Common components include establishing what is actually being taken, reviewing the indication and expected benefit of each medicine, assessing interactions and duplication, and identifying both unnecessary treatment and important omissions.

Medication reconciliation is the process of establishing an accurate medication list and resolving discrepancies, particularly during transitions between care settings. It is distinct from a comprehensive medication review, which evaluates the appropriateness of treatment.

Deprescribing is a planned, supervised process of reducing or stopping medicines when their potential harms outweigh their benefits or when they no longer fit treatment goals. It is one component of optimization, not a synonym for it. A review may also lead to dose adjustment, substitution, simplification, or addition of a necessary treatment. Some medicines require gradual withdrawal because abrupt discontinuation can produce withdrawal effects or recurrence of the condition being treated.

These processes commonly involve prescribers, professionals in pharmacy, and other members of the care team. Shared decision-making incorporates the person’s preferences and priorities alongside clinical evidence.

Assessment tools and evidence limitations

Explicit tools such as the Beers Criteria and STOPP/START criteria identify potentially inappropriate medicines, prescribing patterns, or treatment omissions in older adults. They support structured review but do not establish that every flagged prescription is inappropriate. Their application depends on clinical circumstances, care setting, and the version used.

Research on polypharmacy interventions includes medication reviews, pharmacist involvement, electronic prescribing support, and multidisciplinary care. Some interventions improve measures of prescribing appropriateness or reduce medicine counts. Effects on hospitalization, mortality, and quality of life are less consistent across studies.

Important limitations include differing definitions of polypharmacy, variation in intervention content, short follow-up, and underrepresentation of people with complex multimorbidity in trials. The World Health Organization includes polypharmacy among the priority areas of its Medication Without Harm patient-safety initiative, emphasizing medication-related harm rather than medicine count alone.